Open

Hidradenitis Suppurativa

The purpose of the study is to learn about the safety and effects of the study medicine (called Bimekizumab) for the treatment of Hidradenitis Suppurativa in adolescents (12 to <18 years of age) and children ≥9 years of age with moderate to severe hidradenitis suppurativa (HS).

Age & Gender

9 years ~ 17 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of the study team and fill out questionnaires. The study also involves vital signs, blood draws, urine testing, physical exams, ECG, Chest x-ray, willingness to provide medical history and use of medications, use of birth control method if applicable, and willingness to take the study medication as directed.

Incentives

Information provided upon request

Total length of participation:
104 weeks

Looking for Specific Volunteers

Able to participate:

must be 12 to <18 years of age
have a diagnosis of HS based on clinical history and physical examination
moderate to severe HS, defined as a total of ≥5 inflammatory lesions
must have HS lesions present in at least 2 distinct anatomic areas
had a history of inadequate response to a course of a systemic antibiotic for treatment of HS

Not eligible if:

have a history of IBD
have active TB disease
have a history of alcohol or drug abuse within the previous 6 months

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Suzy Caballero
nieves_caballero@med.unc.edu

Primary Visit Location

UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 400, Chapel Hill, NC 27516, USA

Additional Study Information

Principal Investigator

Chris Sayed
Dermatology-Research

Study Type

Clinical or Medical
Interventional

Study Topics

Skin, Hair, and Nails

IRB Number

25-0405

ClinicalTrials.gov

NCT06921850

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.